Anelixis Therapeutics has completed its Phase 1 clinical trial testing AT-1501, an investigational antibody, in healthy volunteers and eight amyotrophic lateral sclerosis (ALS) patients. The company also announced it has secured the funds to proceed to a Phase 2 clinical trial of AT-1501. The results of the Phase…

Kadimastem plans to submit an amendment to the protocol of its ongoing Phase 1/2a trial in Israel assessing the use of AstroRx, an “off-the-shelf” stem cell therapy, for the treatment of amyotrophic lateral sclerosis (ALS). The company wants to change the planned dosage in one of the…

The ALS Association Golden West Chapter has honored Mitsubishi Tanabe Pharma America (MTPA) with its Essey Commitment to Cures award for advancing research and trials into treatments for amyotrophic lateral sclerosis (ALS) and other efforts. The presentation took place Nov. 15 in San Francisco at the 2019 Champions…

Amyotrophic lateral sclerosis (ALS) is highly prevalent among young U.S. war veterans deployed post-9/11, particularly Air Force personnel, tactical operation officers, and health care workers, a recent study suggests. The findings suggest that there is an early onset of ALS among deployed military service members, the researchers said. Titled…

Aquestive Therapeutics has granted a development and commercialization license to Zambon Pharma for its investigational oral film formulation of riluzole as a treatment for amyotrophic lateral sclerosis (ALS) in the European Union (EU). Under the terms of the agreement, Zambon will be…

Small molecule inhibitors that block the activity of SARM1 — an enzyme that plays a key role in nerve cell degeneration — prevent the degeneration of axons in mice and cellular models of disease, a preclinical study has found. These findings may be the first steps towards the development…

The non-invasive delivery of ultrasound waves in a controlled, targeted manner can be safely used to open the blood-brain barrier in people with amyotrophic lateral sclerosis (ALS), giving temporary access to their motor cortex, results from a first-in-human trial show. The approach — called magnetic resonance guided…

Aural Analytics and the Translational Genomics Research Institute (TGen) will collaborate on a new acupuncture clinical trial to assess how the treatment affects speech in people recently diagnosed with amyotrophic lateral sclerosis (ALS). TGen, a nonprofit medical research institute, will sponsor…

Radicava (edaravone), an intravenous treatment for amyotrophic lateral sclerosis (ALS), is now commercially available in Canada, Mitsubishi Tanabe Pharma Canada (MTP-CA) has announced. The treatment was approved in Canada in October 2018, and has since been under the regulatory process that determines how, where, and at what…

Exercise appears to benefit people with amyotrophic lateral sclerosis (ALS) by normalizing molecular changes that occur at the junction of nerves and muscles, but by degrees that depend on the type of exercise, a study in a mouse model of ALS suggests. While running and swimming both lessened the profound molecular…